ESR1 and breast cancer: A combination of the best possible HER family targeted therapies (lumretuzumab plus pertuzumab) with an endocrine therapy (fulvestrant) subsequently lead to superior and long-lasting efficacy in an ER+/HER2-low/HER3+ breast cancer mouse xenograft model (Fig 4).